Effect of ticagrelor for acute non-ST-segment elevation myocardial infarction patents underwent percutaneous coronary intervention

  Objective  To investigate the effect of ticagrelor on acute non-ST-segment elevation myocardial infarction (NSTEMI) after percutaneous coronary intervention (PCI).

  Methods  A total of 240 patients with NSTEMI treated by PCI were randomly divided into Ticagrelor group (n=120) and clopidogrel group (n=120). Serum levels of interleukin-6 (IL-6), C reactive protein (CRP) and platelet aggregation rate were measured before and after PCI. The incidence of adverse cardiovascular events (MACE) at 30 days after PCI was compared between the two groups.

  Results  There were no significant differences in platelet aggregation rate, serum IL-6 and CRP levels between the two groups before PCI (P>0.05). The platelet aggregation rate, serum IL-6 and CRP levels in tigrillo group were significantly lower than those in clopidogrel group at 1, 7, 30 d after PCI (P < 0.05). The incidence of MACE was significantly lower than that of clopidogrel group (P < 0.05).

  Conclusion  Tigrillo has better anti-platelet aggregation and anti-inflammatory effects than clopidogrel, which can significantly reduce the risk of MACE and improve the prognosis of patients withNSTEMI interventional therapy.